(Not giving up) the marathon race of Met targeting therapy: Are we there yet?

Patrick C. Ma

doi:10.1158/1078-0432.CCR-18-3739

(Not giving up) the marathon race of Met targeting therapy: Are we there yet?

Patrick C. Ma

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Among the various MET aberrations, MET amplification and METex14 have emerged as valid predictive biomarkers for MET inhibition. Despite challenges that have limited the development of MET inhibitors, we can learn from the latest efforts in biomarker-based therapy to better identify the patients who will benefit from treatment with these agents.

Original language	English (US)
Pages (from-to)	2375-2378
Number of pages	4
Journal	Clinical Cancer Research
Volume	25
Issue number	8
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-3739
State	Published - Apr 15 2019

All Science Journal Classification (ASJC) codes

General Medicine

Access to Document

10.1158/1078-0432.CCR-18-3739

Cite this

@article{c9ef7bab635b4bf191dda9c05e653c55,

title = "(Not giving up) the marathon race of Met targeting therapy: Are we there yet?",

abstract = "Among the various MET aberrations, MET amplification and METex14 have emerged as valid predictive biomarkers for MET inhibition. Despite challenges that have limited the development of MET inhibitors, we can learn from the latest efforts in biomarker-based therapy to better identify the patients who will benefit from treatment with these agents.",

author = "Ma, {Patrick C.}",

note = "Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",

year = "2019",

month = apr,

day = "15",

doi = "10.1158/1078-0432.CCR-18-3739",

language = "English (US)",

volume = "25",

pages = "2375--2378",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "8",

}

TY - JOUR

T1 - (Not giving up) the marathon race of Met targeting therapy

T2 - Are we there yet?

AU - Ma, Patrick C.

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Among the various MET aberrations, MET amplification and METex14 have emerged as valid predictive biomarkers for MET inhibition. Despite challenges that have limited the development of MET inhibitors, we can learn from the latest efforts in biomarker-based therapy to better identify the patients who will benefit from treatment with these agents.

AB - Among the various MET aberrations, MET amplification and METex14 have emerged as valid predictive biomarkers for MET inhibition. Despite challenges that have limited the development of MET inhibitors, we can learn from the latest efforts in biomarker-based therapy to better identify the patients who will benefit from treatment with these agents.

UR - http://www.scopus.com/inward/record.url?scp=85064746425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064746425&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-3739

DO - 10.1158/1078-0432.CCR-18-3739

M3 - Article

C2 - 30770350

AN - SCOPUS:85064746425

SN - 1078-0432

VL - 25

SP - 2375

EP - 2378

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 8

ER -

(Not giving up) the marathon race of Met targeting therapy: Are we there yet?

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this